{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:28:25Z","timestamp":1787682505141,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671750"],"award-info":[{"award-number":["81671750"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Natural Science Foundation of Guangdong province","award":["2016A030312008"],"award-info":[{"award-number":["2016A030312008"]}]},{"name":"International Cooperation and Exchanges","award":["81320108015"],"award-info":[{"award-number":["81320108015"]}]},{"name":"Shantou University Medical College Clinical Research Enhancement Initiative of China","award":["201422"],"award-info":[{"award-number":["201422"]}]},{"name":"Guangdong Provincial Key Laboratory on Breast Cancer Diagnosis and Treatment Research"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.canlet.2018.01.009","type":"journal-article","created":{"date-parts":[[2018,1,6]],"date-time":"2018-01-06T18:49:39Z","timestamp":1515264579000},"page":"196-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation"],"prefix":"10.1016","volume":"418","author":[{"given":"K.X.","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.H.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.M.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4709-2446","authenticated-orcid":false,"given":"C.W.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2018.01.009_bib1","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","article-title":"Breast cancer subtypes and the risk of local and regional relapse","volume":"28","author":"Voduc","year":"2010","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2018.01.009_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00126334-200010010-00001","article-title":"Strong in\u00a0vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100","volume":"25","author":"Tremblay","year":"2000","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.canlet.2018.01.009_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1586\/era.09.189","article-title":"Triple-negative\/basal-like breast cancer: clinical, pathologic and molecular features","volume":"10","author":"Venkitaraman","year":"2010","journal-title":"Expet Rev. Anticancer Ther."},{"key":"10.1016\/j.canlet.2018.01.009_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/annonc\/mdl306","article-title":"High-dose chemotherapy for triple negative breast cancer","volume":"18","author":"De Giorgi","year":"2007","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.canlet.2018.01.009_bib5","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1200\/JCO.2010.33.4714","article-title":"Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy","volume":"29","author":"Abdulkarim","year":"2011","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clini. Oncol."},{"key":"10.1016\/j.canlet.2018.01.009_bib6","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2007.14.5565","article-title":"Breast Cancer Cooperative, Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group","volume":"26","author":"Kyndi","year":"2008","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2018.01.009_bib7","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20120601","article-title":"Breast cancer subtypes: response to radiotherapy and potential radiosensitisation","volume":"86","author":"Langlands","year":"2013","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.canlet.2018.01.009_bib8","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1038\/bjc.2013.502","article-title":"Pre-irradiation of mouse mammary gland stimulates cancer cell migration and development of lung metastases","volume":"109","author":"Bouchard","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2018.01.009_bib9","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1038\/onc.2012.578","article-title":"Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis","volume":"32","author":"Semenza","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.01.009_bib10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2018.01.009_bib11","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.1426","article-title":"Chemokines in tumor progression and metastasis","volume":"4","author":"Sarvaiya","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2018.01.009_bib12","doi-asserted-by":"crossref","first-page":"10893","DOI":"10.18632\/oncotarget.3535","article-title":"Hypoxia-inducible factor 1alpha (HIF-1alpha) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1alpha\/CXCR4 pathway in non-small cell lung carcinoma cells","volume":"6","author":"Gu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2018.01.009_bib13","first-page":"926","article-title":"Irradiation enhances expression of cxcr4 in murine glioma cells via HIF-1alpha-independent pathway","volume":"42","author":"Zhou","year":"2014","journal-title":"J.\u00a0Int. Med. Res."},{"key":"10.1016\/j.canlet.2018.01.009_bib14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10585-014-9673-2","article-title":"CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model","volume":"31","author":"Domanska","year":"2014","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.canlet.2018.01.009_bib15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1593\/tlo.13559","article-title":"Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study","volume":"6","author":"Ali","year":"2013","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.canlet.2018.01.009_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ijc.23083","article-title":"Involvement of SDF-1alpha\/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma","volume":"122","author":"Kajiyama","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2018.01.009_bib17","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2018.01.009_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.18632\/oncotarget.2741","article-title":"Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin","volume":"6","author":"Liang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2018.01.009_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1566524013666131121115656","article-title":"Aberrant expression of CXCR4 significantly contributes to metastasis and predicts poor clinical outcome in breast cancer","volume":"14","author":"Yang","year":"2014","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.canlet.2018.01.009_bib20","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/nm.3391","article-title":"Tumor metastasis: moving new biological insights into the clinic","volume":"19","author":"Wan","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2018.01.009_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2011.197","article-title":"Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4","volume":"26","author":"Rettig","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.01.009_bib22","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1182\/blood-2005-09-3592","article-title":"AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates","volume":"107","author":"Larochelle","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.01.009_bib23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-016-0434-9","article-title":"A\u00a0randomized, open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC)","volume":"11","author":"Hainsworth","year":"2016","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.canlet.2018.01.009_bib24","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1158\/1078-0432.CCR-13-2686","article-title":"A\u00a0phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer","volume":"20","author":"Galsky","year":"2014","journal-title":"Clin. Cancer Res. Official J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2018.01.009_bib25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.18632\/oncoscience.311","article-title":"Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide","volume":"3","author":"Rios","year":"2016","journal-title":"Oncoscience"},{"key":"10.1016\/j.canlet.2018.01.009_bib26","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","article-title":"Role of cell cycle in mediating sensitivity to radiotherapy","volume":"59","author":"Pawlik","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2018.01.009_bib27","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.1038\/cddis.2014.365","article-title":"Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer","volume":"5","author":"Loriot","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2018.01.009_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13014-015-0474-9","article-title":"Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in\u00a0vitro and clinical pharmacokinetic studies in head and neck cancer","volume":"10","author":"Zerp","year":"2015","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.canlet.2018.01.009_bib29","doi-asserted-by":"crossref","first-page":"26615","DOI":"10.18632\/oncotarget.5666","article-title":"Radiation-induced lung damage promotes breast cancer lung-metastasis through CXCR4 signaling","volume":"6","author":"Feys","year":"2015","journal-title":"Oncotarget"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518300314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518300314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T04:45:38Z","timestamp":1603601138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383518300314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":29,"alternative-id":["S0304383518300314"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2018.01.009","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2018.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}